Viatris to buy Pacira BioSciences in $1.65 billion cash deal

Viatris announced a definitive agreement to acquire all outstanding shares of Pacira BioSciences for $36.50 in cash per share, valuing the target at $1.65 billion. The transaction adds Pacira’s two U.S. non‑opioid pain products, EXPAREL and ZILRETTA, to Viatris’ portfolio and is slated to close by the end of 2026, subject to customary conditions. Viatris said the purchase will be immediately accretive to its guidance and will be funded mainly with cash and a modest amount of short‑term borrowing. Pacira will become a wholly‑owned subsidiary and its Nasdaq listing will be terminated.

The deal expands Viatris’ presence in the growing non‑opioid pain market and is expected to lift its near‑term revenue and earnings, according to the companies’ own guidance. Pacira shareholders will receive cash at a 45% premium, and the transaction will remove Pacira’s shares from public trading.

  • 1Viatris will pay $36.50 per Pacira share in cash.
  • 2The cash consideration totals $1.65 billion in aggregate equity value.
  • 3Pacira generated approximately $746 million of revenue in the twelve months ended June 30, 2026.
  • 4Pacira reported about $177 million of adjusted EBITDA for the same period.
  • 5The transaction is expected to close by the end of 2026, subject to a majority tender and regulatory approvals.
  • 6Viatris plans to fund the purchase primarily with excess cash and the remainder with short‑term borrowings, with minimal impact on its gross leverage ratio.

Sources